MEGTE 160MG TABLETS

MEGTE 160mg Tablets is a prescription targeted hormonal anticancer medicine containing enzalutamide, an androgen receptor inhibitor used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). This oral therapy plays a vital role in advanced prostate cancer management by directly targeting androgen-driven tumor growth.

Enzalutamide in MEGTE works by blocking androgen receptor signaling pathways that stimulate prostate cancer cell growth and survival. Inhibiting the action of male hormones helps slow disease progression, reduce tumor spread, and improve overall treatment outcomes. The convenient oral tablet form supports long-term targeted therapy as prescribed by an oncologist.

The MEGTE 160 mg Tablet ensures consistent quality, safety, and therapeutic effectiveness. It is a prescription-only oncology medicine intended for oral use and must be taken strictly under the supervision of a qualified oncologist. MEGTE provides a reliable and clinically proven treatment option for patients with advanced prostate cancer

Product Features

• Oral anti-androgen targeted therapy
• Contains Enzalutamide 160 mg
• Used in advanced prostate cancer
• Androgen receptor signaling inhibitor
• Once-daily oral dosing (as prescribed)
• High bioavailability oral formulation
• Manufactured under GMP-compliant standards
• Prescription-required oncology medicine

How It Helps

• Blocks androgen receptor signaling to slow prostate cancer growth
• Reduces tumor progression in metastatic castration-resistant and hormone-sensitive prostate cancer
• Supports effective long-term oral targeted therapy under an oncologist’s supervision
• Helps improve overall disease management and patient outcomes